GH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Guardant Health Inc (GH) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has positive catalysts such as recent FDA approvals and strong analyst ratings, insider selling, lack of proprietary trading signals, and a bearish short-term stock trend suggest caution. It is recommended to hold off on investing until a clearer entry point or stronger signals emerge.
The MACD is below 0 and negatively contracting, indicating a bearish signal. RSI is neutral at 62.983. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is near resistance levels (R1: 133.657). Short-term stock trends suggest a potential decline (-2.39% next day, -5.11% next week, -5.2% next month).
Recent FDA approval of Guardant360 CDx liquid biopsy test, inclusion of Guardant Shield in ACS guidelines, and strong analyst ratings with multiple price target increases (highest at $185).
Significant insider selling (1274.28% increase last month), no recent congress trading data, and hedge funds showing neutral sentiment. Short-term stock trends indicate potential declines.
No financial data available for analysis.
Analysts are highly optimistic with multiple Outperform/Buy ratings and price targets ranging from $129 to $185. Analysts cite structural growth, FDA approvals, and underpenetrated markets as key drivers.
